Risk communication strategy
This article was originally published in The Tan Sheet
Executive Summary
FDA says the Risk Communication Advisory Committee will discuss the draft strategic plan and offer further advice on priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. At its previous meeting, the committee emphasized the need for FDA to assess the effectiveness of its communications as a part of ensuring safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)
You may also be interested in...
FDA Risk Communication Research May Follow Critical Path To Avoid OMB
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.